Antiherpesvirus Activities of Two Novel 4′-Thiothymidine Derivatives, KAY-2-41 and KAH-39-149, Are Dependent on Viral and Cellular Thymidine Kinases
Open Access
- 1 August 2014
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (8) , 4328-4340
Abstract
The emergence of drug-resistant herpesviruses represents a significant problem in clinical practice, primarily in immunocompromised patients. Furthermore, effective antiviral therapies against gammaherpesvirus-associated diseases are lacking. Here, we present two thiothymidine derivatives, KAY-2-41 and KAH-39-149, with different spectra of antiviral activity from those of the reference antiherpetic drugs, showing inhibitory activities against herpes simplex virus, varicella-zoster virus (VZV), and particularly against Epstein-Barr virus, with high selectivityin vitro. While KAY-2-41- and KAH-39-149-resistant herpesviruses were found to harbor mutations in the viral thymidine kinase (TK), these mutations conferred only low levels of resistance to these drugs but high levels to other TK-dependent drugs. Also, antiviral assays in HeLa TK-deficient cells showed a lack of KAY-2-41 and KAH-39-149 activities against herpes simplex virus 1 (HSV-1) and HSV-2 TK-deficient mutants. Furthermore, enzymatic TK assays showed the ability of HSV-1 TK, VZV TK, and cellular TK1 and TK2 to recognize and phosphorylate KAY-2-41 and KAH-39-149. These results demonstrate that the compounds depend on both viral and host TKs to exert antiviral activity. Additionally, the antiviral efficacy of KAH-39-149 proved to be superior to that of KAY-2-41 in a mouse model of gammaherpesvirus infection, highlighting the potential of this class of antiviral agents for further development as selective therapeutics against Epstein-Barr virus.Keywords
This publication has 47 references indexed in Scilit:
- In Vitro -Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus DrugsJournal of Virology, 2012
- Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and ManagementAntimicrobial Agents and Chemotherapy, 2011
- Inhibition of Herpesvirus Replication by 5-Substituted 4′-Thiopyrimidine NucleosidesAntimicrobial Agents and Chemotherapy, 2009
- Activities of Certain 5-Substituted 4′-Thiopyrimidine Nucleosides against Orthopoxvirus InfectionsAntimicrobial Agents and Chemotherapy, 2009
- Acyclovir‐Resistant Corneal HSV‐1 Isolates from Patients with Herpetic KeratitisThe Journal of Infectious Diseases, 2008
- Synthesis and Anti-HIV Activity of 4′-Substituted 4′-Thiothymidines: A New Entry Based on Nucleophilic Substitution of the 4′-Acetoxy GroupJournal of Medicinal Chemistry, 2008
- Herpes Simplex Virus Thymidine Kinase Mutations Associated with Resistance to Acyclovir: a Site-Directed Mutagenesis StudyAntimicrobial Agents and Chemotherapy, 2005
- Identification and characterization of the conserved nucleoside-binding sites in the Epstein-Barr virus thymidine kinaseBiochemical Journal, 2004
- Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovirJournal of General Virology, 2003
- Epstein–Barr virus post‐transplant lymphoproliferative disease and virus‐specific therapy: pharmacological re‐activation of viral target genes with arginine butyrateTransplant Infectious Disease, 2001